Alex Sapir - 04 Mar 2024 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
President & Chief Executive Officer, Director
Signature
/s/ Greg Tourangeau as attorney-in-fact for Alex Sapir
Issuer symbol
FULC
Transactions as of
04 Mar 2024
Net transactions value
+$492,028
Form type
4
Filing time
05 Mar 2024, 16:15:17 UTC
Previous filing
03 Jul 2023
Next filing
08 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FULC Common Stock Purchase $492,028 +43,360 $11.35 43,360 04 Mar 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.50, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

Remarks:

President & Chief Executive Officer